The Hepatitis B Cure That Took Sixty Years to Arrive

For sixty years, chronic hepatitis B has been one of medicine's most stubborn unsolved problems. The virus infects more than 240 million people worldwide, silently destroying liver tissue over decades, and stands as the leading cause of liver cancer globally. Doctors have had tools to suppress it, but not to eliminate it. On May 28, 2026, that calculus shifted in a meaningful way when GSK published Phase 3 data in the New England Journal of Medicine showing that its antisense oligonucleotide bepirovirsen functionally cured nearly one in five patients across two large clinical trials. For a disease where the existing standard of care achieves functional cure in less than one percent of patients, that number is not incremental. It is a different category of result.

What Functional Cure Actually Means

The term "functional cure" carries specific meaning in hepatitis B, and it is worth being precise about what it does and does not represent. A functional cure is defined as the sustained loss of hepatitis B surface antigen (HBsAg) from the blood, ideally accompanied by the development of antibodies against it, along with undetectable viral DNA. It does not mean the virus is completely eradicated from the body. The hepatitis B virus integrates into the host genome, and traces of viral DNA can persist in liver cells even after surface antigen clearance. What functional cure does mean is that the immune system has regained control, viral replication has been durably suppressed, and the risk of long-term liver complications, including cirrhosis and hepatocellular carcinoma, is substantially reduced. For patients who have been managing a chronic infection for years or decades, that outcome represents a meaningful change in their prognosis.

The B-Well 1 and B-Well 2 trials enrolled 1,838 patients who were already receiving daily nucleos(t)ide analogue therapy, the current standard of care that suppresses viral replication but rarely eliminates the virus. After 24 weeks of weekly bepirovirsen injections followed by continued standard treatment, 19 percent of all treated patients achieved functional cure at the 72-week assessment. In the subset of patients who entered the trial with lower levels of HBsAg, below 1,000 international units per milliliter, the functional cure rate rose to 26 percent. These are not cherry-picked subgroup numbers. They are the primary results of two large, well-designed Phase 3 trials, and they were published in the most rigorous peer-reviewed journal in medicine.

How Bepirovirsen Works

Bepirovirsen is an antisense oligonucleotide, a short synthetic strand of nucleic acid designed to bind to specific sequences of viral RNA and trigger their degradation. GSK licensed the compound from Ionis Pharmaceuticals in 2019 and has since built its entire hepatitis B pipeline around it. The drug works through three distinct mechanisms simultaneously. It disrupts the pre-genomic RNA that the virus uses to copy its DNA genome. It degrades the messenger RNA that produces HBsAg, the surface protein that floods the bloodstream and exhausts the immune system. And it appears to stimulate innate immune responses in the liver, helping to reinvigorate an immune system that the virus has spent years suppressing through its decoy strategy of releasing empty viral shells.

That third mechanism, the immune reinvigoration component, may be the most important. Chronic hepatitis B is not simply a problem of viral replication. It is a problem of immune exhaustion. The virus has evolved to overwhelm the immune system with enormous quantities of surface antigen, distracting it from mounting an effective response against infected cells. By simultaneously reducing HBsAg production and stimulating innate immunity, bepirovirsen appears to break that cycle in a way that nucleos(t)ide analogues, which only address replication, cannot.

The Safety Picture and What Comes Next

The safety profile of bepirovirsen is not without complexity. More patients in the treatment arm experienced grade 3 or higher adverse events compared to placebo, with the most common being elevations in liver enzymes. Four patients discontinued therapy due to ALT flares. The investigators interpret these enzyme elevations as a sign of efficacy rather than toxicity, reflecting immune-mediated clearance of infected hepatocytes. That interpretation is scientifically plausible, but it also means the drug requires careful monitoring and a clinical infrastructure capable of managing hepatic flares. That is a real-world consideration that will shape how bepirovirsen is deployed once approved.

GSK has already submitted bepirovirsen for regulatory approval in the United States, Japan, Europe, and China. The FDA is expected to make a decision by October 2026. The company is also developing a combination strategy, pairing bepirovirsen with a small interfering RNA candidate called DAP/TOM, licensed from Arrowhead Pharmaceuticals via Johnson and Johnson, that is designed to reduce HBsAg levels even in patients with very high viral loads, potentially expanding the population that can benefit from bepirovirsen's mechanism.

The Broader Significance

The hepatitis B story is a useful lens through which to examine how the pharmaceutical industry allocates attention and resources. Hepatitis C, which affects far fewer people globally, received enormous investment after the discovery of direct-acting antivirals and was effectively cured in the early 2010s. Hepatitis B, which infects roughly ten times as many people and kills more of them, has received comparatively less transformative investment, partly because the existing nucleos(t)ide analogues generate steady revenue without curing the disease, and partly because the biology of functional cure is genuinely harder to achieve.

Bepirovirsen does not cure everyone. A 19 percent functional cure rate means that 81 percent of patients in the B-Well trials did not achieve that outcome. GSK's combination strategy with DAP/TOM is explicitly designed to address that gap, and the company has a suite of earlier-stage candidates targeting additional mechanisms. The path to curing hepatitis B in the majority of patients will likely require combination regimens, just as hepatitis C required combinations of direct-acting antivirals to achieve near-universal cure rates. What bepirovirsen establishes is that functional cure is achievable at scale, that the immune system can be reinvigorated after years of viral suppression, and that the biology of the problem is now yielding to the tools of modern molecular medicine. After sixty years of managing a disease without curing it, that is a meaningful place to be.